keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell Lung cancer mediastinal staging

keyword
https://www.readbyqxmd.com/read/29033013/clinical-prognosis-of-superior-versus-basal-segment-stage-i-non-small-cell-lung%C3%A2-cancer
#1
Yoshinori Handa, Yasuhiro Tsutani, Norifumi Tsubokawa, Keizo Misumi, Hideaki Hanaki, Yoshihiro Miyata, Morihito Okada
BACKGROUND: Despite its extensive size, variations in the clinicopathologic features of tumors in the lower lobe have been little studied. The present study investigated the prognostic differences in tumors originating from the superior and basal segments of the lower lobe in patients with non-small cell lung cancer. METHODS: Data of 134 patients who underwent lobectomy or segmentectomy with systematic nodal dissection for clinical stage I, radiologically solid-dominant, non-small cell lung cancer in the superior segment (n = 60) or basal segment (n = 74) between April 2007 and December 2015 were retrospectively reviewed...
October 12, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28973110/association-of-pathologic-nodal-staging-quality-with-survival-among-patients-with-non-small-cell-lung-cancer-after-resection-with-curative-intent
#2
Matthew P Smeltzer, Nicholas R Faris, Meredith A Ray, Raymond U Osarogiagbon
Importance: Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differences not only in cancer biology but also in the thoroughness of the nodal examination. Objective: To determine whether survival was affected by sequentially more stringent definitions of pN staging quality in a cohort of patients with NSCLC after resection with curative intent...
September 28, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28958031/pathological-lymph-node-involvement-is-not-a-predictor-of-adverse-outcomes-in-patients-undergoing-thoracoscopic-lobectomy-for-lung-cancer
#3
Udo Abah, Gianluca Casali, Timothy James Peacock Batchelor, Eveline Internullo, Rakesh Krishnadas, Natasha Joshi, Samson Egbulonu, Frances Warden, Vito Domenico Bruno, Douglas George West
OBJECTIVES: As the practice of video-assisted thoracoscopic surgery (VATS) lobectomy gains widespread acceptance, the complexity of procedures attempted increases and the stage of tumour that may be safely approached remains controversial. We examined the impact of nodal involvement with respect to perioperative outcomes after VATS lobectomy. METHODS: All patients listed for VATS lobectomy for non-small-cell lung cancer at our institution from 2012 to 2016 were analysed...
August 29, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28942077/transcervical-extended-mediastinal-lymphadenectomy-experience-from-a-north-american-cancer-center
#4
Sai Yendamuri, Athar Battoo, Grace Dy, Hongbin Chen, Jorge Gomez, Anurag K Singh, Mark Hennon, Chukwumere E Nwogu, Elisabeth U Dexter, Miriam Huang, Anthony Picone, Todd L Demmy
BACKGROUND: Accurate staging of the mediastinum is a critical element of therapeutic decision making in non-small cell lung cancer. We sought to determine the utility of transcervical extended mediastinal lymphadenectomy (TEMLA) in staging non-small cell lung cancer for large central tumors and after induction therapy. METHODS: A retrospective record review was performed of all patients who underwent TEMLA at our institution from 2010 to 2015. Clinical stage as assessed by positron emission tomography integrated with computed tomography (PET-CT), stage as assessed by TEMLA, final pathologic stage, lymph node yield, and clinical characteristics of tumors were assessed along with TEMLA-related perioperative morbidity...
September 21, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28932523/mediastinal-lymph-node-resection-in-stage-ia-non-small-cell-lung-cancer-with-small-nodule-is-it-mandatory
#5
EDITORIAL
Dong Kwan Kim
No abstract text is available yet for this article.
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28919394/concomitant-chemotherapy-and-radiotherapy-with-sbrt-boost-for-unresectable-stage-iii-non-small-cell-lung-cancer-a-phase-i-study
#6
Kristin A Higgins, Rathi N Pillai, Zhengjia Chen, Sibo Tian, Chao Zhang, Pretesh Patel, Suchita Pakkala, Jay Shelton, Seth D Force, Felix G Fernandez, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Jeffrey D Bradley, Walter J Curran
PURPOSE: Stereotactic Body Radiation Therapy (SBRT) is now the standard of care in medically inoperable stage I non-small cell lung cancer, yielding high rates of local control. It is unknown if SBRT can be safely utilized in the locally advanced NSCLC setting. This multi-institution phase I study evaluated the safety of 44 Gy conventionally fractionated thoracic radiation with concurrent chemotherapy plus a dose escalated SBRT boost to both the primary tumor and involved mediastinal lymph nodes...
September 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28906073/salvage-radiotherapy-for-regional-lymph-node-oligo-recurrence-after-radical-surgery-of-non-small-cell-lung-cancer
#7
Ki Ho Seol, Jeong Eun Lee, Joon Yong Cho, Deok Heon Lee, Yangki Seok, Min Kyu Kang
BACKGROUND: Currently, evidence-based guidelines for salvage therapy to treat mediastinal lymph node (LN) oligo-recurrence in post-resection non-small cell lung cancer (NSCLC) are limited. In patients previously treated by surgery without irradiation, radiotherapy (RT) might be safely utilized. We evaluate the clinical outcomes of salvage RT for patients with LN oligo-recurrence that developed after radical surgery for NSCLC. METHODS: Thirty-one patients with stage I-IIIA NSCLC who developed regional LN oligo-recurrence between 2008 and 2013 were reviewed...
September 14, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28857362/diagnostic-performance-of-endobronchial-ultrasound-guided-mediastinal-lymph-node-sampling-in-early-stage-non-small-cell-lung-cancer-a-prospective-study
#8
Macarena R Vial, Oisin J O'Connell, Horiana B Grosu, Mike Hernandez, Laila Noor, Roberto F Casal, John Stewart, Mona Sarkiss, Carlos A Jimenez, David Rice, Reza Mehran, David E Ost, George A Eapen
BACKGROUND AND OBJECTIVE: Standard nodal staging of lung cancer consists of positron emission tomography/computed tomography (PET/CT), followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) if PET/CT shows mediastinal lymphadenopathy. Sensitivity of EBUS-TBNA in patients with N0/N1 disease by PET/CT is unclear and largely based on retrospective studies. We assessed the sensitivity of EBUS-TBNA in this setting. METHODS: We enrolled patients with proven or suspected lung cancer staged as N0/N1 by PET/CT and without metastatic disease (M0), who underwent staging EBUS-TBNA...
August 30, 2017: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/28856088/syndrome-of-inappropriate-secretion-of-anti-diuretic-hormone-siadh-as-an-initial-presenting-sign-of-non-small-cell-lung-cancer-case-report-and-literature-review
#9
Praneet Iyer, Mohammad Ibrahim, Waqas Siddiqui, Ahmed Dirweesh
Association of SIADH with malignancy was first reported in 1957, when it was described in two patients with bronchogenic carcinoma. While the association with small cell lung cancer (SCLC) is well known, that with non small cell lung cancer (NSCLC) has been rarely reported. We report a case of 70 year old male who was found to have hyponatremia secondary to SIADH. Radiological tests revealed right hilar lung mass with mediastinal adenopathy. Bronchoscopic biopsy revealed non-small cell lung cancer of type squamous cell...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/28843357/the-role-of-thoracic-surgery-in-the-therapeutic-management-of-metastatic-non-small-cell-lung-cancer
#10
REVIEW
Elizabeth A David, James M Clark, David T Cooke, Joy Melnikow, Karen Kelly, Robert J Canter
INTRODUCTION: The majority of non-small cell lung cancer (NSCLC) patients are diagnosed with advanced stage disease for whom the prognosis is poor and survival is typically measured in months. Standard therapeutic treatment regimens for patients with stage IV NSCLC typically include chemotherapy and palliative radiation. Despite newer regimens that may include molecularly targeted therapy and immunotherapy, the overall 5-year survival for stage IV disease remains low at 4-6%. Although therapeutic surgery is performed in a minority of cases, accumulating data suggest that thoracic surgery may play several beneficial roles for these patients...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28812120/risk-adapted-robotic-stereotactic-body-radiation-therapy-for-inoperable-early-stage-non-small-cell-lung-cancer
#11
Susanne Temming, Martin Kocher, Erich Stoelben, Lars Hagmeyer, De-Hua Chang, Konrad Frank, Khosro Hekmat, Juergen Wolf, Wolfgang W Baus, Robert Semrau, Christian Baues, S Marnitz
PURPOSE: To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients. METHODS: From 2012 to 2016, 106 patients (median age 74 years, range 50-94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent (18)F-fluorodeoxyglucose positron-emission tomography (18-FDG-PET) and/or endobronchial ultrasound (EBUS)-guided lymph node biopsy or mediastinoscopy...
August 15, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28800837/outcomes-of-invasive-mediastinal-nodal-staging-versus-positron-emission-tomography-staging-alone-for-early-stage-non-small-cell-lung-cancer-treated-with-stereotactic-body-radiation-therapy
#12
Caitlin A Schonewolf, Vivek Verma, Carl M Post, Abigail T Berman, Melissa A Frick, Anil Vachani, Chi Lin, Charles B Simone
BACKGROUND: The benefit of invasive mediastinal nodal staging (IMNS) in addition to positron emission tomography-computed tomography (PET/CT) is undefined for early stage non-small cell lung cancer (NSCLC). This multi-institutional investigation aimed to evaluate outcomes and patterns of failure in patients staged with PET/CT with or without additional IMNS. METHODS: Two academic centers assessed all consecutive patients staged with PET/CT for early-stage, primary lung NSCLC (cT1-2aN0M0) treated with SBRT...
July 14, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28740931/the-relationship-between-cardiac-radiation-dose-and-mediastinal-lymph-node-involvement-in-stage-iii-non-small-cell-lung-cancer-patients
#13
Laura K McNew, Stephen R Bowen, Olga Gopan, Matthew J Nyflot, Shilpen A Patel, Jing Zeng, Ramesh Rengan
PURPOSE: The results from Radiation Therapy Oncology Group (RTOG) 0617, a dose escalation trial that compared treatment with 60 Gy versus 74 Gy for patients with stage III non-small cell lung cancer (NSCLC), suggested that in these patients, the heart dose from radiation therapy correlates with survival. In particular, the study noted that patients with a high heart V5 and V30 had a poorer overall survival; however, the exact cause of this correlation is not known. We hypothesize that heart dose may be a surrogate for mediastinal nodal involvement, which has prognostic value in NSCLC...
April 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/28740431/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-cancer-a-guide-for-the-medical-oncologist
#14
REVIEW
Sassine Ghanem, Sandy El Bitar, Sami Hossri, Chanudi Weerasinghe, Jean Paul Atallah
Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28733723/an-individualized-radiation-dose-escalation-trial-in-non-small-cell-lung-cancer-based-on-fdg-pet-imaging
#15
Marie Wanet, Antoine Delor, François-Xavier Hanin, Benoît Ghaye, Aline Van Maanen, Vincent Remouchamps, Christian Clermont, Samuel Goossens, John Aldo Lee, Guillaume Janssens, Anne Bol, Xavier Geets
AIM: The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. PATIENTS AND METHODS: A total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes)...
July 21, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28684006/evolution-in-the-surgical-care-of-patients-with-non-small-cell-lung-cancer-in-the-mid-south-quality-of-surgical-resection-cohort
#16
MULTICENTER STUDY
Nicholas R Faris, Matthew P Smeltzer, Fujin Lu, Carrie L Fehnel, Nibedita Chakraborty, Cheryl L Houston-Harris, E Todd Robbins, Raymond S Signore, Laura M McHugh, Bradley A Wolf, Lynn Wiggins, Paul Levy, Vishal Sachdev, Raymond U Osarogiagbon
Surgery is the most important curative treatment modality for patients with early-stage non-small cell lung cancer (NSCLC). We examined the pattern of surgical resection for NSCLC in a high incidence and mortality region of the United States over a 10-year period (2004-2013) in the context of a regional surgical quality improvement initiative. We abstracted patient-level data on all resections at 11 hospitals in 4 contiguous Dartmouth Hospital Referral Regions in North Mississippi, East Arkansas, and West Tennessee...
April 2017: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28683462/endobronchial-ultrasound-guided-transbronchial-needle-aspiration-for-staging-of-patients-with-non-small-cell-lung-cancer-without-mediastinal-involvement-at-positron-emission-tomography-computed-tomography
#17
Therese Maria Henriette Naur, Lars Konge, Paul Frost Clementsen
BACKGROUND: Staging of lung cancer is essential to the treatment, which is curative only in cases of localized disease. Previous studies have suggested that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is unnecessary when positron emission tomography-computed tomography (PET-CT) shows no mediastinal involvement. OBJECTIVE: The aim of the study was to investigate how often EBUS-TBNA resulted in a clinically relevant upstaging in patients with lung cancer without mediastinal involvement at PET-CT...
July 6, 2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28680205/an-unusual-case-of-myocardial-localization-of-non-small-cell-lung-cancer-metastasis-a-case-report-and-review-of-literature
#18
Luca Tagliabue, Giulia Manfrinato, Andrea Luciani
Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) is useful for staging non-small cell lung cancer (NSCLC), decide the appropriate initial management, and evaluate the response to therapy. Metastatic spreading is very common during the course of NSCLC and principal localization sites include: regional and mediastinal lymph nodes and organs such as the contralateral lung parenchyma, bone, brain, adrenal gland, pleura, and liver. Myocardial localizations are very rare, often asymptomatic, and difficult to diagnose...
July 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28671758/comparison-of-mediastinal-lymph-node-status-and-relapse-pattern-in-clinical-stage-iiia-non-small-cell-lung-cancer-patients-treated-with-neoadjuvant-chemotherapy-versus-upfront-surgery-a-single-center-experience
#19
Milan Savic, Milica Kontic, Maja Ercegovac, Jelena Stojsic, Slavisa Bascarevic, Dejan Moskovljevic, Marko Kostic, Radomir Vesovic, Spasoje Popevic, Marija Laban, Jelena Markovic, Dragana Jovanovic
BACKGROUND: In spite of the progress made in neoadjuvant therapy for operable non small-cell lung cancer (NSCLC), many issues remain unsolved, especially in locally advanced stage IIIA. METHODS: Retrospective data of 163 patients diagnosed with stage IIIA NSCLC after surgery was analyzed. The patients were divided into two groups: a preoperative chemotherapy group including 59 patients who received platinum-etoposide doublet treatment before surgery, and an upfront surgery group including 104 patients for whom surgical resection was the first treatment step...
September 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28669706/sinoatrial-node-toxicity-after-stereotactic-ablative-radiation-therapy-to-lung-tumors
#20
Yushen Qian, Han Zhu, Erqi L Pollom, Ben Y Durkee, Aadel A Chaudhuri, Michael F Gensheimer, Maximilian Diehn, David B Shultz, Billy W Loo
PURPOSE: Stereotactic ablative radiation therapy (SABR) is an established treatment for selected lung tumors. Sinoatrial node (SAN) toxicity after thoracic SABR has not been reported in the literature. We sought to understand the risk of SAN toxicity owing to incidental dose to the SAN from SABR. METHODS AND MATERIALS: We conducted a retrospective review of patients with early-stage lung cancer or limited pulmonary metastases who underwent thoracic SABR to a right-sided central lung tumor (within 2 cm of the mainstem bronchus or other mediastinal structures) between January 2008 and December 2014, analyzed a subset whose treatment imparted dose to the SAN exceeding 10% of the prescription dose, and examined patient and treatment dosimetric characteristics...
April 13, 2017: Practical Radiation Oncology
keyword
keyword
10511
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"